Kronn D.F.Day-Salvatore D.WUH-LIANG HWUJones S.A.Nakamura K.Okuyama T.Swoboda K.J.Kishnani P.S.2020-12-162020-12-1620170031-4005https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021822034&doi=10.1542%2fpeds.2016-0280E&partnerID=40&md5=859e073b97e64bd93d5386ca07450701https://scholars.lib.ntu.edu.tw/handle/123456789/525832After a Pompe disease diagnosis is confirmed in infants identified through newborn screening (NBS), when and if to start treatment with enzyme replacement therapy (ERT) with alglucosidase alfa must be determined. In classic infantile-onset Pompe disease, ERT should start as soon as possible. Once started, regular, routine follow-up is necessary to monitor for treatment effects, disease progression, and adverse effects. Decision-making for when or if to start ERT in late-onset Pompe disease (LOPD) is more challenging because patients typically have no measurable signs or symptoms or predictable time of symptom onset at NBS. With LOPD, adequate, ongoing follow-up and assessments for onset or progression of signs and symptoms are important to track disease state and monitor and adjust care before and after treatment is started. Because numerous tests are used to monitor patients at variable frequencies, a standardized approach across centers is lacking. Significant variability in patient assessments may result in missed opportunities for early intervention. Management of Pompe disease requires a comprehensive, multidisciplinary approach with timely disease-specific interventions that target the underlying disease process and symptom-specific manifestations. Regardless of how identified, all patients who have signs or symptoms of the disease require coordinated medical care and follow-up tailored to individual needs throughout their lives. The Pompe Disease Newborn Screening Working Group identifies key considerations before starting and during ERT; summarizes what comprises an indication to start ERT; and provides guidance on how to determine appropriate patient management and monitoring and guide the frequency and type of follow-up assessments for all patients identified through NBS. ? 2017 by the American Academy of Pediatrics.[SDGs]SDG3alpha glucosidase; Article; asymptomatic disease; audiology; central venous catheter; clinical feature; cost; disease severity; enzyme therapy; follow up; gastroenterology; genetic counseling; glycogen storage disease type 2; health status; heart function; human; immunological tolerance; immunomodulation; motor development; neuromuscular function; newborn; newborn screening; onset age; patient care; practice guideline; priority journal; respiratory function; symptom; treatment planning; vascular access; disease exacerbation; enzyme replacement; glycogen storage disease type 2; newborn screening; procedures; Disease Progression; Enzyme Replacement Therapy; Glycogen Storage Disease Type II; Humans; Infant, Newborn; Neonatal Screeningjournal article10.1542/peds.2016-0280E291626752-s2.0-85021822034